Controlled preparation and antitumor efficacy of vitamin E TPGS-functionalized PLGA nanoparticles for delivery of paclitaxel

Wang, Guoying; Yu, Bo; Wu, Yuequn; Huang, Baolin; Yuan, Yuan; Liu, Chang Sheng

doi:10.1016/j.ijpharm.2013.02.004

Cited by 72 publications

(27 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Wang et al prepared polymeric nanoparticle containing paclitaxel of size ~130nm with 80% encapsulation efficiency by inverse-phase nanoprecipitation method 55 . In this method, an aqueous phase is slowly added to an organic phase and the nanoparticles are allowed to form 55 .…”

Section: Accepted Manuscriptmentioning

confidence: 99%

See 1 more Smart Citation

Inhalable nanoparticulate powders for respiratory delivery

Muralidharan

Malapit

Mallory

et al. 2015

Nanomedicine: Nanotechnology, Biology and Medicine

182

123

View full text Add to dashboard Cite

show abstract

Section: Accepted Manuscriptmentioning

confidence: 99%

“…In this method, an aqueous phase is slowly added to an organic phase and the nanoparticles are allowed to form 55 .…”

Section: Accepted Manuscriptmentioning

confidence: 99%

Inhalable nanoparticulate powders for respiratory delivery

Muralidharan

Malapit

Mallory

et al. 2015

Nanomedicine: Nanotechnology, Biology and Medicine

182

123

View full text Add to dashboard Cite

show abstract

“…It has been reported that the labeling of lipophilic nanocarriers using the indocarbocyanine-dye family provides a reliable means of near-infrared reflection imaging. 66 Figure 12A and B show the lung fluorescence images captured at 1, 3, 6, 24, and 48 hours after injection of DiR-PLGA NPs and SpdDiR-PLGA NPs in nude mice. Fluorescence accumulation in the lung zone was observed in both groups, but SpdDiR-PLGA NPs displayed more intensive signals at each time point.…”

Section: In Vivo Fluorescence Imagingmentioning

confidence: 99%

Spermidine-mediated poly(lactic-<em>co</em>-glycolic acid) nanoparticles containing fluorofenidone for the treatment of idiopathic pulmonary fibrosis

Tang¹,

Li²,

Guo³

et al. 2017

IJN

View full text Add to dashboard Cite

Idiopathic pulmonary fibrosis is a progressive, fatal lung disease with poor survival. The advances made in deciphering this disease have led to the approval of different antifibrotic molecules, such as pirfenidone and nintedanib. An increasing number of studies with particles (liposomes, nanoparticles [NPs], microspheres, nanopolymersomes, and nanoliposomes) modified with different functional groups have demonstrated improvement in lung-targeted drug delivery. In the present study, we prepared, characterized, and evaluated spermidine (Spd)-modified poly(lactic- co -glycolic acid) (PLGA) NPs as carriers for fluorofenidone (AKF) to improve the antifibrotic efficacy of this drug in the lung. Spd-AKF-PLGA NPs were prepared and functionalized by modified solvent evaporation with Spd and polyethylene glycol (PEG)-PLGA groups. The size of Spd-AKF-PLGA NPs was 172.5±4.3 nm. AKF release from NPs was shown to fit the Higuchi model. A549 cellular uptake of an Spd–coumarin (Cou)-6-PLGA NP group was found to be almost twice as high as that of the Cou-6-PLGA NP group. Free Spd and difluoromethylornithine (DFMO) were preincubated in A549 cells to prove uptake of Spd-Cou-6-PLGA NPs via a polyamine-transport system. As a result, the uptake of Spd-Cou-6-PLGA NPs significantly decreased with increased Spd concentrations in incubation. At higher Spd concentrations of 50 and 500 µM, uptake of Spd-Cou-6-PLGA NPs reduced 0.34- and 0.49-fold from that without Spd pretreatment. After pretreatment with DFMO for 36 hours, cellular uptake of Spd-Cou-6-PLGA NPs reached 1.26-fold compared to the untreated DFMO group. In a biodistribution study, the drug-targeting index of Spd-AKF-PLGA NPs in the lung was 3.62- and 4.66-fold that of AKF-PLGA NPs and AKF solution, respectively. This suggested that Spd-AKF-PLGA NPs accumulated effectively in the lung. Lung-histopathology changes and collagen deposition were observed by H&E staining and Masson staining in an efficacy study. In the Spd-AKF-PLGA NP group, damage was further improved compared to the AKF-PLGA NP group and AKF-solution group. The results indicated that Spd-AKF-PLGA NPs are able to be effective nanocarriers for anti–pulmonary fibrosis therapy.

show abstract

“…35 In vivo, the PTX-triggered antitumor effect is a more complex biological process than in vitro, in which PTX should first be targeted to the tumor site and then exert inhibitory effects on tumor cells. 36 In vivo tissue distribution studies revealed that the distribution of PTX was altered when delivered through the PTX-SNPs, which resulted in significantly higher PTX accumulations in tumors than PTX-NPs and Taxol ® ( Figure 6A, B, C, and D). To visually observe and confirm the targeted tumor tissue ability of SNPs, we chose coumarin 6 as the fluorescence probe and observed the frozen tumor tissue slices at 1 ( Figure 6E) and 8 hours ( Figure 6F) after administration of different formulations.…”

Section: Discussionmentioning

confidence: 99%

Sulfatide-containing lipid perfluorooctylbromide nanoparticles as paclitaxel vehicles targeting breast carcinoma

Xiao¹,

Qin²,

Yang³

et al. 2014

IJN

View full text Add to dashboard Cite

Targeted nanoparticle (NP) delivery vehicles are emerging technologies, the full potential of which has yet to be realized. Sulfatide is known to bind to extracellular matrix glycoproteins that are highly expressed in breast tumors. In this study, we report for the first time the combination of sulfatide and lipid perfluorooctylbromide NPs as a targeted breast cancer delivery vehicle for paclitaxel (PTX). PTX-sulfatide-containing lipid perfluorooctylbromide NPs (PTX-SNPs) were prepared using the emulsion/solvent evaporation method. PTX-SNPs exhibited a spherical shape, small particle size, high encapsulation efficiency, and a biphasic release in phosphate-buffered solution. The cytotoxicity study and cell apoptosis assay revealed that blank sulfatide-containing lipid perfluorooctylbromide NPs (SNPs) had no cytotoxicity, whereas PTX-SNPs had greater EMT6 cytotoxicity levels than PTX-lipid perfluorooctylbromide NPs (PTX-NPs) and free PTX. An in vitro cellular uptake study revealed that SNPs can deliver greater amounts of drug with more efficient and immediate access to intracellular targets. In vivo biodistribution measured using high-performance liquid chromatography confirmed that the PTX-SNPs can target breast tumor tissues to increase the accumulation of PTX in these tissues. The in vivo tumor inhibition ability of PTX-SNPs was remarkably higher than PTX-NPs and free PTX. Furthermore, toxicity studies suggested that the blank SNPs had no systemic toxicity. All results suggested that SNPs may serve as efficient PTX delivery vehicles targeting breast carcinoma.

show abstract

Controlled preparation and antitumor efficacy of vitamin E TPGS-functionalized PLGA nanoparticles for delivery of paclitaxel

Cited by 72 publications

References 36 publications

Inhalable nanoparticulate powders for respiratory delivery

Inhalable nanoparticulate powders for respiratory delivery

Spermidine-mediated poly(lactic-<em>co</em>-glycolic acid) nanoparticles containing fluorofenidone for the treatment of idiopathic pulmonary fibrosis

Sulfatide-containing lipid perfluorooctylbromide nanoparticles as paclitaxel vehicles targeting breast carcinoma

Contact Info

Product

Resources

About

Controlled preparation and antitumor efficacy of vitamin E TPGS-functionalized PLGA nanoparticles for delivery of paclitaxel

Cited by 72 publications

References 36 publications

Inhalable nanoparticulate powders for respiratory delivery

Inhalable nanoparticulate powders for respiratory delivery

Spermidine-mediated poly(lactic-<em>co</em>-glycolic acid)&nbsp;nanoparticles containing fluorofenidone for the treatment of idiopathic pulmonary fibrosis

Sulfatide-containing lipid perfluorooctylbromide nanoparticles as paclitaxel vehicles targeting breast carcinoma

Contact Info

Product

Resources

About

Spermidine-mediated poly(lactic-<em>co</em>-glycolic acid) nanoparticles containing fluorofenidone for the treatment of idiopathic pulmonary fibrosis